Replies to post #243098 on Biotech Values

[DewDiligence]

AMTI—(-23%)—Phase-2 in UC misses primary endpoint:

https://finance.yahoo.com/news/applied-molecular-transport-announces-top-120000682.html

Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8